Evidence map›Paper›PMID 42550607›Full record

ArticleThe Journal of clinical investigation2026

Genomic characterization of therapy-associated polyposis reveals an alkylating mutational signature from prior treatment.

Yashika Parashar, Zsofia Sztupinszki, Aurel György Prósz, Xiaolu Wang, Pratyusha Bala, Shweta Cavale, Chinedu Ukaegbu, Sapna Syngal, Asaf Maoz, Leah Biller and 4 more

Abstract read
In one paragraph

Article in The Journal of clinical investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yashika ParasharDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Zsofia SztupinszkiDanish Cancer Institute, Copenhagen, Denmark.
Aurel György PrószDanish Cancer Institute, Copenhagen, Denmark.
Xiaolu WangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Pratyusha BalaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Shweta CavaleDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Chinedu UkaegbuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Sapna SyngalDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Asaf MaozDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Leah BillerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Ramona LimDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Matthew B YurgelunDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Zoltan SzallasiDanish Cancer Institute, Copenhagen, Denmark.
Nilay S SethiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

Funding

Molecular mechanisms of developmental reprogramming in colorectal cancerR01CA292507 · NCI · DANA-FARBER CANCER INST · PI Nilay Sethi · 2024 to 2026
$2.8M
NCI NIH HHS R01 CA292507
6 · The paper itself

Abstract

This study shows that chemotherapy leaves lasting DNA scars in precancerous colon polyps decades after treatment, helping explain a rare late complication in childhood cancer survivors.

Indexed as

Adenomatous Polyposis ColiColonic PolypsMutationHumansColorectal cancerGastroenterologyMolecular geneticsOncology

Identifiers

PMID42550607
PMCPMC13626825

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.